Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Beginner's Mind

Beginner's Mind artwork

EP 158 - Rafael Rosengarten: Why 90% of Cancer Drugs Fail — and the Radical AI Fix You’ve Never Heard Of

May 16, 20252 hr 3 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Most cancer drugs fail. Not because the science is wrong - because we’re solving the wrong problems. The cost? Over $2 billion per failure. And for the patient waiting on a miracle - there’s no second chance. Behind the headlines of “precision medicine,” there’s a deeper story nobody’s telling. Until now. 🎯 Enter Rafael Rosengarten, the scientist-turned-founder who’s rewriting the rules of drug development. In this gripping conversation, we unpack how RNA, AI, and deep empathy could finally close the loop between biology, data, and the patient in the room. 🎧 Watch now to explore: 1️⃣ Why drug failure isn’t a tech problem - it’s a strategy problem 2️⃣ How “information companions” will guide every medicine to the right patient 3️⃣ What pharma keeps getting wrong about biomarkers - and how to fix it 4️⃣ The untold story behind turning down a chef’s job on a Mediterranean yacht 5️⃣ The real reason Genialis may one day go out of business (and why Rafael hopes it does) 👤 About Rafael Rosengarten Rafael is CEO and co-founder of Genialis, the RNA biomarker company reshaping precision oncology. From academic labs to Michelin-star kitchens, his journey is anything but linear - but his mission is clear: make medicine make sense. With partners across pharma, diagnostics, and AI, Genialis is creating a world where every patient gets the treatment they actually need. 💬 Quotes That Might Shift Your Thinking: (00:58:37) “Our AI biomarkers de-risk clinical trials, slashing costs and saving lives.” (01:54:46) “Every drug will have an information companion guiding it to the right patient.” (01:14:32) “AI should free humans for empathy and creativity, not replace them.” (00:14:13) “We now have the tools to treat every cancer as unique to each patient.” (01:31:38) “Stop selling technology; sell solutions to real problems.” 🧭 Timestamps to Explore: (00:03:52) Inside the World’s Largest Medical Center (00:10:30) How AI Is Rewiring Precision Medicine (00:13:51) Why Precision Medicine Is Scaling Now (00:17:34) Startups Must Solve Market Needs First (00:23:53) Culture First, Then Business: Startup Blueprint (00:27:57) Cancer Isn’t One Disease - It’s Thousands (00:31:44) Predicting Drug Success with AI Biology (00:36:40) Reimagining Biomarkers Using RNA and AI (00:47:45) Why Early Detection Still Saves Lives (00:57:30) Why Most Cancer Drugs Still Fail (00:58:37) AI Biomarkers That De-Risk Clinical Trials (01:09:42) Rethinking Dosage with Predictive Algorithms (01:13:33) Why Human Intuition Still Matters in Science (01:36:41) The Crystal Ball Question Pharma Can’t Ignore (01:50:19) The moment where time disappears - and the real future begins. (01:53:39) Every Drug Will Have an AI Companion 🔔 Let’s Rebuild Trust in Medicine - Together If this episode sparked a new thought - or just gave you pause - don’t let it end here. Subscribe. Share it with someone who still believes medicine can be both scientific and deeply human. Every action brings in minds like Rafael’s… and gets us one step closer to treatments that truly heal. 🎧 Watch now - and discover how medicine gets smarter, safer, and more personal. Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Spark 20: Alex Dang | Everyone Agrees? Think Again. How Venture Capitalists Decide

    Nov 1, 202629 minAudio

    Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...

    Credit the people on this episode

  2. EP 185: Ivy Nguyen | IQ, EQ and the Execution Quotient Investors Fund

    Oct 18, 20261 hr 4 minAudio

    The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...

    Credit the people on this episode

  3. EP 184: Ivy Nguyen | 10,000 AI Pitches and the One Test That Matters

    Oct 15, 202659 minAudio

    In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...

    Credit the people on this episode

  4. EP 183: Marie Schroeder | Send the Rough Deck, Not the Perfect One

    Sep 27, 20262 hr 5 minAudio

    A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it...

    Credit the people on this episode

  5. #182 - How to Lead When You Don't Know Where You Are Going: 4 Lessons from Ben Horowitz (Part 2 of 2)

    Sep 8, 202657 minAudio

    What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...

    Credit the people on this episode